American Bio Medica (ABMC) 10-Q 14 Nov 16 2016 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 14, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Entity Registrant Name	AMERICAN BIO MEDICA CORP
Entity Central Index Key	896,747
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ABMC
Entity Common Stock, Shares Outstanding		28,458,173

Condensed Balance Sheets

Condensed Balance Sheets - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Current assets
Cash and cash equivalents	$ 221,000	$ 158,000
Accounts receivable, net of allowance for doubtful accounts of $50,000 at September 30, 2016 and December 31, 2015	721,000	672,000
Inventory, net of allowance of $495,000 at September 30, 2016 and $432,000 at December 31, 2015	1,556,000	1,746,000
Prepaid expenses and other current assets	61,000	40,000
Total current assets	2,559,000	2,616,000
Property, plant and equipment, net	844,000	910,000
Patents, net	70,000	67,000
Other assets	21,000	14,000
Deferred finance costs - line of credit, net	55,000	79,000
Total assets	3,549,000	3,686,000
Current liabilities
Accounts payable	305,000	373,000
Accrued expenses and other current liabilities	225,000	212,000
Wages payable	281,000	292,000
Line of credit	736,000	777,000
Current portion of long-term debt	75,000	75,000
Total current liabilities	1,622,000	1,729,000
Other liabilities	19,000	38,000
Related party note payable	0	124,000
Long-term debt, net of current portion and deferred finance costs	730,000	834,000
Total liabilities	2,371,000	2,725,000
COMMITMENTS AND CONTINGENCIES
Stockholders' equity:
Preferred stock; par value $.01 per share; 5,000,000 shares authorized, none issued and outstanding at September 30, 2016 and December 31, 2015	0	0
Common stock; par value $.01 per share; 50,000,000 shares authorized; 28,458,173 issued and outstanding at September 30, 2016 and 26,032,930 issued and outstanding at December 31, 2015	285,000	260,000
Additional paid-in capital	20,979,000	20,656,000
Accumulated deficit	(20,086,000)	(19,955,000)
Total stockholders’ equity	1,178,000	961,000
Total liabilities and stockholders’ equity	$ 3,549,000	$ 3,686,000

Condensed Balance Sheets (Paren

Condensed Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Allowance For Doubtful Accounts Receivable, Current (in dollars)	$ 50,000	$ 50,000
Inventory Valuation Reserves	$ 495,000	$ 432,000
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	28,458,173	26,032,930
Common stock, shares outstanding	28,458,173	26,032,930

Condensed Statements of Operati

Condensed Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Net sales	$ 1,417,000	$ 1,590,000	$ 4,392,000	$ 4,785,000
Cost of goods sold	806,000	823,000	2,441,000	2,543,000
Gross profit	611,000	767,000	1,951,000	2,242,000
Operating expenses:
Research and development	28,000	45,000	136,000	125,000
Selling and marketing	275,000	291,000	827,000	899,000
General and administrative	368,000	370,000	1,124,000	1,298,000
Operating Expenses, Total	671,000	706,000	2,087,000	2,322,000
Operating income / (loss)	(60,000)	61,000	(136,000)	(80,000)
Other income / (expense):
Interest income	0	0	0	(1,000)
Interest expense	(71,000)	(63,000)	(192,000)	(196,000)
Other income	44,000	0	200,000	147,000
Other income / (expense), Total	(27,000)	(63,000)	8,000	(50,000)
Net loss before tax	(87,000)	(2,000)	(128,000)	(130,000)
Income tax expense	(1,000)	0	(2,000)	0
Net loss	$ (88,000)	$ (2,000)	$ (130,000)	$ (130,000)
Basic and diluted loss per common share (in dollars per share)	$ 0	$ 0	$ (0.01)	$ (0.01)
Weighted average number of shares outstanding - basic and diluted (in shares)	27,284,308	26,032,930	27,056,216	25,557,021

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows - USD ($)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Cash flows from operating activities:
Net loss	$ (130,000)	$ (130,000)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	69,000	70,000
Amortization of deferred finance and debt discount	90,000	187,000
Provision for bad debts	0	(1,000)
Provision for slow moving and obsolete inventory	63,000	63,000
Share-based payment expense	49,000	27,000
Changes in:
Accounts receivable	(49,000)	13,000
Inventory	127,000	(189,000)
Prepaid expenses and other current assets	21,000	5,000
Accounts payable	(38,000)	19,000
Accrued expenses and other current liabilities	(6,000)	18,000
Wages payable	(11,000)	23,000
Net cash provided by operating activities	185,000	105,000
Cash flows from investing activities:
Purchase of property, plant and equipment	0	(10,000)
Patent application costs	(6,000)	(4,000)
Net cash used in investing activities	(6,000)	(14,000)
Cash flows from financing activities:
Proceeds from (payments on) debt financing	(75,000)	130,000
Deferred finance costs	0	(205,000)
Proceeds from lines of credit	4,609,000	5,090,000
Payments on lines of credit	(4,650,000)	(5,234,000)
Net cash used in financing activities	(116,000)	(219,000)
Net Increase / (decrease) in cash and cash equivalents	63,000	(128,000)
Cash and cash equivalents - beginning of period	158,000	352,000
Cash and cash equivalents - end of period	221,000	224,000
Supplemental disclosures of cash flow information
Cash paid during period for interest	119,000	176,000
Cash paid during period for taxes	2,000	0
Consulting expense prepaid with restricted stock	49,000	0
Debt issuance cost paid with restricted stock	96,000	0
Related party note payable paid with restricted stock	$ 154,000	$ 0

Basis of Reporting

Basis of Reporting	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Accounting [Text Block]	Note A - Basis of Reporting The accompanying unaudited interim condensed financial statements of American Bio Medica Corporation (the “Company”) have been prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Regulation S-X. Accordingly, these unaudited interim condensed financial statements do not include all information and footnotes required by U.S. GAAP for complete financial statement presentation. These unaudited interim condensed financial statements should be read in conjunction with audited financial statements and related notes contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015. In the opinion of management, the interim condensed financial statements include all normal, recurring adjustments which are considered necessary for a fair presentation of the financial position of the Company September 30, 2016, the results of operations for the three and nine month periods ended September 30, 2016 and September 30, 2015, and cash flows for the nine month periods ended September 30, 2016, and September 30, 2015. Operating results for the three and nine months ended September 30, 2016 are not necessarily indicative of results that may be expected for the year ending December 31, 2016. Amounts at December 31, 2015 are derived from audited financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015. Reclassifications have been made to the audited financial statements for the year ended December 31, 2015 to conform to the presentation of the financial statements for the three and nine months ended September 30, 2016. During the nine months ended September 30, 2016, there were no significant changes to the Company’s critical accounting policies, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015. The preparation of these interim condensed financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, the Company evaluates estimates, including those related to product returns, bad debts, inventories, income taxes, warranty obligations, contingencies and litigation. The Company bases estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. These unaudited interim condensed financial statements have been prepared assuming that the Company will continue as a going concern and, accordingly, do not include any adjustments that might result from the outcome of this uncertainty. The independent registered public accounting firm’s report on the financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015, contained an explanatory paragraph regarding the Company’s ability to continue as a going concern. As of the date of this report, the Company’s current cash balances, together with cash generated from future operations and amounts available under current credit facilities may not be sufficient to fund operations for the next 12 months if sales levels do not improve. If cash generated from operations is not sufficient to satisfy the Company’s working capital and capital expenditure requirements, the Company will be required to sell additional equity or obtain additional credit facilities. There is no assurance that such financing will be available or that the Company will be able to complete financing on satisfactory terms, if at all. In August 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-15, “Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments”. The ASU addresses specific cash flow items with the objective of reducing existing diversity in practice, including the treatment of distributions received from equity method investees. The updated standard will be effective for the Company on January 1, 2018 and must be applied retrospectively to all periods presented; early adoption is permitted. The Company does not expect the updated standard to have a material impact on our financial position or results of operations. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers, which provides guidance for revenue recognition. The update’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current guidance. Examples of the use of judgments and estimates may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The update also requires more detailed disclosures to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The update provides for two transition methods to the new guidance: a retrospective approach and a modified retrospective approach. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, as a revision to ASU 2014-09, which revised the effective date to fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is permitted but not prior to periods beginning after December 15, 2016 (i.e. the original adoption date per ASU No. 2014-09). In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers: Principal versus Agent Considerations, which clarifies certain aspects of the principal-versus-agent guidance, including how an entity should identify the unit of accounting for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements, such as service transactions. The amendments also reframe the indicators to focus on evidence that an entity is acting as a principal rather than as an agent. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing, which clarifies how an entity should evaluate the nature of its promise in granting a license of intellectual property, which will determine whether it recognizes revenue over time or at a point in time. The amendments also clarify when a promised good or service is separately identifiable (i.e., distinct within the context of the contract) and allow entities to disregard items that are immaterial in the context of a contract. And finally, in May 2016, FASB issued ASU No. 2016-12, “Revenue from Contracts with Customers”. This update amends the new revenue recognition guidance on transition, collectability, noncash consideration and the presentation of sales and other similar taxes. The amendments also clarify how an entity should evaluate the collectability threshold and when an entity can recognize nonrefundable consideration received as revenue if an arrangement does not meet the standard's contract criteria. We are currently evaluating the transition methods and the impact of adoption of this ASU on our consolidated financial statements. Recently Adopted Standards In April 2015, the FASB issued ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs”. This Update is part of its initiative to reduce complexity in accounting standards (the Simplification Initiative). The Board received feedback that having different balance sheet presentation requirements for debt issuance costs and debt discount and premium creates unnecessary complexity. Recognizing debt issuance costs as a deferred charge (that is, an asset) also is different from the guidance in International Financial Reporting Standards (IFRS), which requires that transaction costs be deducted from the carrying value of the financial liability and not recorded as separate assets. Additionally, the requirement to recognize debt issuance costs as deferred charges conflicts with the guidance in FASB Concepts Statement No. 6, Elements of Financial Statements, which states that debt issuance costs are similar to debt discounts and in effect reduce the proceeds of borrowing, thereby increasing the effective interest rate. Concepts Statement 6 further states that debt issuance costs cannot be an asset because they provide no future economic benefit. To simplify presentation of debt issuance costs, the amendments in this Update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this Update. For public business entities, the amendments in this Update were effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The Company adopted this ASU in the first quarter 2016. The Company also adopted ASU No. 2015-15, “Interest-Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line of Credit Arrangements” in the first quarter 2016; ASU No. 2015-15 clarifies guidance on the presentation and subsequent measurement of debt issuance costs associated with line of credit arrangements. The adoption of ASU No. 2015-15 did not have any impact on our financials statements. In January 2015, the FASB issued ASU No 2015-01, “Income Statement – Extraordinary and Unusual Items”. This ASU is part of FASB’s initiative to reduce complexity in the account standards by eliminating the concept of extraordinary items from GAAP. The amendments eliminate the requirements for reporting entities to consider whether an underlying event or transaction is extraordinary, however, the presentation and disclosure guidance for items that are unusual in nature or occur infrequently is retained and is expanded to include items that are both unusual in nature and infrequently occurring. This update applies to all entities and was effective for fiscal years, and interim periods within the fiscal year, beginning after December 15, 2015. We adopted this ASU in the first quarter 2016, and it did not have any impact on our financial statements. Certain items have been reclassified from the prior years to conform to the current year presentation. More specifically, certain debt issuance costs and deferred finance costs were reclassified from an asset to a reduction against the long-term liability (as a result of the adoption of ASU No. 2015-03), and $ 75,000

Inventory

Inventory	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	Note B – Inventory Inventory is comprised of the following: September 30, 2016 December 31, 2015 Raw Materials $ 1,054,000 $ 1,208,000 Work In Process 440,000 399,000 Finished Goods 557,000 571,000 Allowance for slow moving and obsolete inventory (495,000) (432,000) $ 1,556,000 $ 1,746,000

Net Loss Per Common Share

Net Loss Per Common Share	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	Note C – Net Loss Per Common Share Basic net loss per common share is calculated by dividing the net loss by the weighted average number of outstanding common shares during the period. Diluted net loss per common share includes the weighted average dilutive effect of stock options and warrants. September 30, 2016 September 30, 2015 Warrants 2,060,000 2,385,000 Options 2,182,000 1,435,000 4,242,000 3,820,000 The number of securities not included in the diluted net loss per share for the three and nine months ended September 30, 2016 (because the effect would have been anti-dilutive) was 4,242,000 The number of securities not included in the diluted net loss per share for the three and nine months ended September 30, 2015 (because the effect would have been anti-dilutive) was 3,820,000

Litigation_Legal Matters

Litigation/Legal Matters	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Legal Matters and Contingencies [Text Block]	Note D – Litigation/Legal Matters From time to time, the Company may be named in legal proceedings in connection with matters that arise during the normal course of business. While the ultimate outcome of any such litigation cannot be predicted, if we are unsuccessful in defending any such litigation, the resulting financial losses could have an adverse effect on the financial position, results of operations and cash flows of the Company. We are not aware of any significant litigation loss contingencies for which management believes it is both probable that a liability has been incurred and that the amount of the loss can be reasonably estimated.

Line of Credit and Debt

Line of Credit and Debt	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note E – Line of Credit and Debt September 30, 2016 December 31, 2015 Loan and Security Agreement with Cherokee Financial, LLC: $ 1,125,000 $ 1,200,000 Crestmark Line of Credit: 736,000 777,000 1,861,000 1,977,000 Less debt discount & issuance costs (Cherokee Financial, LLC Loan) (320,000) (291,000) Total debt $ 1,541,000 $ 1,686,000 Current portion $ 811,000 $ 852,000 Long-term portion $ 730,000 $ 834,000 LOAN AND SECURITY AGREEMENT WITH CHEROKEE FINANCIAL, LLC On March 26, 2015, the Company entered into a LSA with Cherokee Financial, LLC (“Cherokee”). The purpose of the Cherokee Loan and Security Agreement (the “Cherokee LSA”) was to refinance, at a better interest rate, the Company’s Series A Debentures and Cantone Asset Management Bridge Loan as well as the Company’s Mortgage Consolidation Loan with First Niagara Bank (“First Niagara”). The Cherokee loan is collateralized by a first security interest in the Company’s real estate and machinery and equipment. Under the Cherokee LSA, the Company was provided the sum of $ 1,200,000 5 8 75,000 March 26, 2020 8 1 1 The Company issued 1.8 600,000 As placement agent for the transaction, Cantone Research, Inc. (“CRI”) received a 5% cash fee on the $1.2 million, or $ 60,000 200,000 196,000 The Company received net proceeds of $ 80,000 1,015,000 60,000 19,000 19,000 3,000 4,000 8 511,000 From these net proceeds, in April 2015, the Company also paid $ 15,000 15 689,000 The Company recognized $ 144,000 72,000 85,000 35,000 49,000 17,000 42,000 17,000 The Company had $ 16,000 13,000 As of September 30, 2016, the balance on the Cherokee LSA was $ 1,125,000 805,000 1,200,000 909,000 LINE OF CREDIT WITH CRESTMARK BANK (“CRESTMARK”) On June 29, 2015 (the “Closing Date”), the Company entered into a three-year Loan and Security Agreement (“LSA”) with Crestmark, a new Senior Lender, to refinance the Company’s Line of Credit with Imperium Commercial Finance, LLC (“Imperium”). The Crestmark Line of Credit is used for working capital and general corporate purposes. Under the LSA, Crestmark is providing the Company with a Line of Credit of up to $ 1,500,000 500,000 The Maximum Amount is subject to an Advance Formula comprised of: 1) 90% of Eligible Accounts Receivables (excluding, receivables remaining unpaid for more than 90 days from the date of invoice and sales made to entities outside of the United States), and 2) up to 40% of eligible inventory plus up to 10% of Eligible Generic Packaging Components not to exceed the lesser of $500,000 (“Inventory Sub-Cap Limit”), or 100% of the Eligible Accounts Receivable. 10,000 350,000 So long as any obligations are due to Crestmark, the Company must comply with a minimum Tangible Net Worth (“TNW”) Covenant. Under the LSA, as amended, the Company must maintain a TNW of at least $ 650,000 50 If the Company terminates the LSA at any time prior to June 29, 2018 (the 3-year anniversary of the LSA), an early exit fee of 2% of the Maximum Amount (plus any additional amounts owed to Crestmark at the time of termination) would be due. In the event of a default of the LSA, which includes but is not limited to, failure of the Company to make any payment when due and non-compliance with the TNW covenant, Crestmark is permitted to charge an Extra Rate. The Extra Rate is the Company’s then current interest rate plus 12.75% per annum. Under the LSA, interest on the Crestmark Line of Credit is at a variable rate based on the Wall Street Journal Prime Rate plus 2% with a floor of 5.25%. As of the date of this report, the interest rate on the Crestmark Line of Credit is 5.25%. In addition to the interest rate, on the Closing Date and on each one-year anniversary date thereafter, the Company will pay Crestmark a Loan Fee of 0.50%, or $7,500, and a Monthly Maintenance Fee of 0.30% of the actual average monthly loan balance from the prior month will be paid to Crestmark. When these additional fees are considered, the rate on the Crestmark Line of Credit is 9.35 12 In addition to the Loan Fee paid to Crestmark on the Closing Date, the Company had to pay a Success Fee (i.e. early termination fee) to Imperium in the amount of $ 50,000 12,000 3,000 50,000 24,000 8,000 8,000 6,000 The Company recognized $ 47,000 21,000 16,000 21,000 Given the nature of the administration of the Crestmark Line of Credit, at September 30, 2016, the Company had $0 in accrued interest expense related to the Crestmark Line of Credit, and there is $0 in additional availability under the Crestmark Line of Credit. As of September 30, 2016, the balance on the Crestmark Line of Credit was $ 736,000 777,000 PRIOR DEBT INSTRUMENTS AFFECTING PRIOR PERIOD FIRST NIAGARA: MORTGAGE CONSOLIDATION LOAN The Company refinanced the mortgage consolidation loan with First Niagara in March 2015. The nine and three months ended September 30, 2016 did not include any expense related to First Niagara loan, while the nine and three months ended September 30, 2015 included $ 5,000 0 DEBENTURE FINANCING/BRIDGE LOAN The Company refinanced the Series A Debentures and associated bridge loan in March 2015. The nine and three months ended September 30, 2016 did not include any expense related to the Series A Debentures while the nine months ended September 30, 2015 included $ 22,000 0 Line of Credit with Imperium The Company refinanced its line of credit with Imperium in June 2015. The nine and three months ended September 30, 2016 did not include any expense related to the Imperium Line of Credit. The nine months ended September 30, 2015 included $ 137,000 69,000 39,000 0

Stock Options and Warrants

Stock Options and Warrants	9 Months Ended
	Sep. 30, 2016
Stockholders Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]	NOTE F – Stock Options and Warrants The Company currently has two non-statutory stock option plans, the Fiscal 2001 Non-statutory Stock Option Plan (the “2001 Plan”) and the 2013 Equity Compensation Plan (the “2013 Plan”). Both plans have been adopted by our Board of Directors and approved by our shareholders. Both the 2001 Plan and the 2013 Plan have options available for future issuance. Any common shares issued as a result of the exercise of stock options would be new common shares issued from our authorized issued shares. During the three months ended September 30, 2016 and the three months ended September 30, 2015, the Company issued 0 Nine months ended September 30, 2016 Nine months ended September 30, 2015 Aggregate Aggregate Weighted Intrinsic Value Weighted Intrinsic Value Average as of Average as of Exercise September 30, Exercise September 30, Shares Price 2016 Shares Price 2015 Options outstanding at beginning of period 1,435,000 $ 0.13 1,295,000 $ 0.27 Granted 830,000 $ 0.11 340,000 $ 0.12 Exercised 0 NA 0 NA Cancelled/expired (83,000) $ 0.19 (200,000) $ 0.90 Options outstanding at end of period 2,182,000 $ 0.13 $ 30,000 1,435,000 0.14 $ 16,300 Options exercisable at end of period 1,184,000 $ 0.14 1,027,000 $ 0.15 Nine month ended September 30, 2016 September 30, 2015 Volatility 62% - 66% 63% - 64% Expected term (years) 10 years 10 years Risk-free interest rate 1.57% - 1.94% 1.92% – 2.33% Dividend yield 0% 0% The Company recognized $ 49,000 27,000 13,000 9,000 As of September 30, 2016, there was approximately $ 57,000 9 20 Warrants Nine month ended September 30, 2016 Nine months ended September 30, 2015 Aggregate Aggregate Weighted Intrinsic Value Weighted Intrinsic Value Average as of Average as of Exercise September 30, Exercise September 30, Shares Price 2016 Shares Price 2015 Warrants outstanding at beginning of period 2,385,000 $ 0.17 3,303,000 $ 0.17 Granted 0 NA 0 NA Exercised 0 NA 0 NA Cancelled/expired (325,000) $ 0.14 (918,000) $ 0.15 Warrants outstanding at end of period 2,060,000 $ 0.18 $ 0 2,385,000 $ 0.17 $ 0 Warrants exercisable at end of period 2,060,000 $ 0.18 2,385,000 $ 0.17 The Company recognized $ 0 100,000 0 As of September 30, 2016, there was $ 0

Related Party Note Payable

Related Party Note Payable	9 Months Ended
	Sep. 30, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE G – Related Party Note Payable As previously disclosed in a Current Report on Form 8-K (filed with the Commission on October 4, 2016), on September 29, 2016, upon request of Edmund M. Jaskiewicz, President of the corporation and former Chairman of the Board, and upon approval of the Company’s Board of Directors, the Company entered into an agreement to exchange Mr. Jaskiewicz’s related party note payable for restricted shares of the Company’s common stock. The extinguishment of the debt was also authorized and consented to by Crestmark Bank, the Company’s line of credit lender, (“Crestmark”); as the debt owed to Mr. Jaskiewicz was subordinate to the Crestmark line of credit debt. On September 30, 2016 and in connection with the agreement indicated above, the Company exchanged the Jaskiewicz related party note in the amount of $ 154,279 1,186,765 The number of common shares to be issued to Mr. Jaskiewicz was determined by a using the average closing price of the Company’s common shares for the ten (10) consecutive trading days preceding the issuance, or $0.13 per share.

Basis of Reporting (Policies)

Basis of Reporting (Policies)	9 Months Ended
	Sep. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Standards In August 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2016-15, “Statement of Cash Flows (Topic 230), Classification of Certain Cash Receipts and Cash Payments”. The ASU addresses specific cash flow items with the objective of reducing existing diversity in practice, including the treatment of distributions received from equity method investees. The updated standard will be effective for the Company on January 1, 2018 and must be applied retrospectively to all periods presented; early adoption is permitted. The Company does not expect the updated standard to have a material impact on our financial position or results of operations. In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers, which provides guidance for revenue recognition. The update’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under current guidance. Examples of the use of judgments and estimates may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. The update also requires more detailed disclosures to enable users of financial statements to understand the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The update provides for two transition methods to the new guidance: a retrospective approach and a modified retrospective approach. In August 2015, the FASB issued ASU No. 2015-14, Revenue from Contracts with Customers: Deferral of the Effective Date, as a revision to ASU 2014-09, which revised the effective date to fiscal years, and interim periods within those years, beginning after December 15, 2017. Early adoption is permitted but not prior to periods beginning after December 15, 2016 (i.e. the original adoption date per ASU No. 2014-09). In March 2016, the FASB issued ASU No. 2016-08, Revenue from Contracts with Customers: Principal versus Agent Considerations, which clarifies certain aspects of the principal-versus-agent guidance, including how an entity should identify the unit of accounting for the principal versus agent evaluation and how it should apply the control principle to certain types of arrangements, such as service transactions. The amendments also reframe the indicators to focus on evidence that an entity is acting as a principal rather than as an agent. In April 2016, the FASB issued ASU No. 2016-10, Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing, which clarifies how an entity should evaluate the nature of its promise in granting a license of intellectual property, which will determine whether it recognizes revenue over time or at a point in time. The amendments also clarify when a promised good or service is separately identifiable (i.e., distinct within the context of the contract) and allow entities to disregard items that are immaterial in the context of a contract. And finally, in May 2016, FASB issued ASU No. 2016-12, “Revenue from Contracts with Customers”. This update amends the new revenue recognition guidance on transition, collectability, noncash consideration and the presentation of sales and other similar taxes. The amendments also clarify how an entity should evaluate the collectability threshold and when an entity can recognize nonrefundable consideration received as revenue if an arrangement does not meet the standard's contract criteria. We are currently evaluating the transition methods and the impact of adoption of this ASU on our consolidated financial statements. Recently Adopted Standards In April 2015, the FASB issued ASU 2015-03, “Simplifying the Presentation of Debt Issuance Costs”. This Update is part of its initiative to reduce complexity in accounting standards (the Simplification Initiative). The Board received feedback that having different balance sheet presentation requirements for debt issuance costs and debt discount and premium creates unnecessary complexity. Recognizing debt issuance costs as a deferred charge (that is, an asset) also is different from the guidance in International Financial Reporting Standards (IFRS), which requires that transaction costs be deducted from the carrying value of the financial liability and not recorded as separate assets. Additionally, the requirement to recognize debt issuance costs as deferred charges conflicts with the guidance in FASB Concepts Statement No. 6, Elements of Financial Statements, which states that debt issuance costs are similar to debt discounts and in effect reduce the proceeds of borrowing, thereby increasing the effective interest rate. Concepts Statement 6 further states that debt issuance costs cannot be an asset because they provide no future economic benefit. To simplify presentation of debt issuance costs, the amendments in this Update require that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by the amendments in this Update. For public business entities, the amendments in this Update were effective for financial statements issued for fiscal years beginning after December 15, 2015, and interim periods within those fiscal years. The Company adopted this ASU in the first quarter 2016. The Company also adopted ASU No. 2015-15, “Interest-Imputation of Interest (Subtopic 835-30): Presentation and Subsequent Measurement of Debt Issuance Costs Associated with Line of Credit Arrangements” in the first quarter 2016; ASU No. 2015-15 clarifies guidance on the presentation and subsequent measurement of debt issuance costs associated with line of credit arrangements. The adoption of ASU No. 2015-15 did not have any impact on our financials statements. In January 2015, the FASB issued ASU No 2015-01, “Income Statement – Extraordinary and Unusual Items”. This ASU is part of FASB’s initiative to reduce complexity in the account standards by eliminating the concept of extraordinary items from GAAP. The amendments eliminate the requirements for reporting entities to consider whether an underlying event or transaction is extraordinary, however, the presentation and disclosure guidance for items that are unusual in nature or occur infrequently is retained and is expanded to include items that are both unusual in nature and infrequently occurring. This update applies to all entities and was effective for fiscal years, and interim periods within the fiscal year, beginning after December 15, 2015. We adopted this ASU in the first quarter 2016, and it did not have any impact on our financial statements.
Reclassification, Policy [Policy Text Block]	Reclassifications Certain items have been reclassified from the prior years to conform to the current year presentation. More specifically, certain debt issuance costs and deferred finance costs were reclassified from an asset to a reduction against the long-term liability (as a result of the adoption of ASU No. 2015-03), and $ 75,000

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory is comprised of the following: September 30, 2016 December 31, 2015 Raw Materials $ 1,054,000 $ 1,208,000 Work In Process 440,000 399,000 Finished Goods 557,000 571,000 Allowance for slow moving and obsolete inventory (495,000) (432,000) $ 1,556,000 $ 1,746,000

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Potential common shares outstanding as of September 30, 2016 and 2015: September 30, 2016 September 30, 2015 Warrants 2,060,000 2,385,000 Options 2,182,000 1,435,000 4,242,000 3,820,000

Line of Credit and Debt (Tables

Line of Credit and Debt (Tables)	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments [Table Text Block]	September 30, 2016 December 31, 2015 Loan and Security Agreement with Cherokee Financial, LLC: $ 1,125,000 $ 1,200,000 Crestmark Line of Credit: 736,000 777,000 1,861,000 1,977,000 Less debt discount & issuance costs (Cherokee Financial, LLC Loan) (320,000) (291,000) Total debt $ 1,541,000 $ 1,686,000 Current portion $ 811,000 $ 852,000 Long-term portion $ 730,000 $ 834,000

Stock Options and Warrants (Tab

Stock Options and Warrants (Tables)	9 Months Ended
	Sep. 30, 2016
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The following table summarizes weighted-average assumptions using the Black-Scholes option-pricing model used on the date of the grants issued during the nine months ended September 30, 2016 and 2015: Nine month ended September 30, 2016 September 30, 2015 Volatility 62% - 66% 63% - 64% Expected term (years) 10 years 10 years Risk-free interest rate 1.57% - 1.94% 1.92% – 2.33% Dividend yield 0% 0%
Employee Stock Option [Member]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Stock option activity for the nine months ended September 30, 2016 and the nine months ended September 30, 2015 is summarized as follows (the figures contained within the tables below have been rounded to the nearest thousand): Nine months ended September 30, 2016 Nine months ended September 30, 2015 Aggregate Aggregate Weighted Intrinsic Value Weighted Intrinsic Value Average as of Average as of Exercise September 30, Exercise September 30, Shares Price 2016 Shares Price 2015 Options outstanding at beginning of period 1,435,000 $ 0.13 1,295,000 $ 0.27 Granted 830,000 $ 0.11 340,000 $ 0.12 Exercised 0 NA 0 NA Cancelled/expired (83,000) $ 0.19 (200,000) $ 0.90 Options outstanding at end of period 2,182,000 $ 0.13 $ 30,000 1,435,000 0.14 $ 16,300 Options exercisable at end of period 1,184,000 $ 0.14 1,027,000 $ 0.15
Warrant [Member]
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Warrant activity during the nine months ended September 30, 2016 and the nine months ended September 30, 2015 is summarized as follows: Nine month ended September 30, 2016 Nine months ended September 30, 2015 Aggregate Aggregate Weighted Intrinsic Value Weighted Intrinsic Value Average as of Average as of Exercise September 30, Exercise September 30, Shares Price 2016 Shares Price 2015 Warrants outstanding at beginning of period 2,385,000 $ 0.17 3,303,000 $ 0.17 Granted 0 NA 0 NA Exercised 0 NA 0 NA Cancelled/expired (325,000) $ 0.14 (918,000) $ 0.15 Warrants outstanding at end of period 2,060,000 $ 0.18 $ 0 2,385,000 $ 0.17 $ 0 Warrants exercisable at end of period 2,060,000 $ 0.18 2,385,000 $ 0.17

Basis of Reporting (Details Tex

Basis of Reporting (Details Textual)	9 Months Ended
	Sep. 30, 2015USD ($)
Other Income [Member]
Summary Of Accounting Policy [Line Items]
Prior Period Reclassification Adjustment	$ 75,000

Inventory (Details)

Inventory (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Inventory [Line Items]
Raw Materials	$ 1,054,000	$ 1,208,000
Work In Process	440,000	399,000
Finished Goods	557,000	571,000
Allowance for slow moving and obsolete inventory	(495,000)	(432,000)
Inventory, Net, Total	$ 1,556,000	$ 1,746,000

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - shares	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Net Income Loss Per Common Share [Line Items]
Weighted Average Number Diluted Shares Outstanding Adjustment	4,242,000	3,820,000
Warrant [Member]
Net Income Loss Per Common Share [Line Items]
Weighted Average Number Diluted Shares Outstanding Adjustment	2,060,000	2,385,000
Stock Option [Member]
Net Income Loss Per Common Share [Line Items]
Weighted Average Number Diluted Shares Outstanding Adjustment	2,182,000	1,435,000

Net Loss Per Common Share (De21

Net Loss Per Common Share (Details Textual) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,242,000	3,820,000	4,242,000	3,820,000

Line of Credit and Debt (Detail

Line of Credit and Debt (Details) - USD ($)	Sep. 30, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 1,861,000	$ 1,977,000
Less debt discount & issuance costs (Cherokee Financial, LLC Loan)	(320,000)	(291,000)
Total debt	1,541,000	1,686,000
Current portion	811,000	852,000
Long-term portion	730,000	834,000
Cherokee Financial LLC [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	1,125,000	1,200,000
Crestmark Line of Credit [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 736,000	$ 777,000

Line of Credit and Debt (Deta23

Line of Credit and Debt (Details Textual)	9 Months Ended
	Sep. 30, 2016USD ($)
Cherokee Financial LLC [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Maturity Date	May 15, 2015
Debt Instrument, Term	5 years
Line of Credit Facility, Interest Rate Description	annual interest rate of 8% plus a 1% annual oversight fee
Line of Credit Facility, Periodic Payment, Principal	$ 75,000
Crestmark Line of Credit [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Term	3 years
Line of Credit Facility, Interest Rate Description	WSJ Prime plus 2% with a floor or 5.25%; loan fee of 0.5% annually & monthly maintenance fee of 0.3% on actual loan balance from prior month. Early termination fee of 3% if terminated in year 1 and 2% if terminated in year 2 or after (and prior to natural expiration)

Line of Credit and Debt - Loan

Line of Credit and Debt - Loan and Security Agreement With Cherokee Financial, LLC (Details Textual) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Apr. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015	Mar. 25, 2015
Line of Credit Facility [Line Items]
Interest Expense, Debt			$ 0		$ 5,000
Debt Instrument, Unamortized Discount		$ 805,000		$ 805,000		$ 909,000
Cherokee Financial LLC [Member]
Line of Credit Facility [Line Items]
Placement Agent Fees				$ 60,000
Debt Instrument, Interest Rate, Stated Percentage		8.00%		8.00%		8.00%
Debt Instrument, Face Amount		$ 1,200,000		$ 1,200,000
Interest Expense, Debt		49,000	42,000	144,000	85,000
Interest Payable		16,000	13,000	$ 16,000	13,000
Annual Fee Percentage				1.00%
Debt Instrument, Annual Principal Payment		75,000		$ 75,000
Debt Instrument, Term				5 years
Administrative Fees Percentage				1.00%
Debt Related Commitment Fees and Debt Issuance Costs		17,000	$ 17,000	$ 72,000	$ 35,000
Cherokee Financial LLC [Member] | Final Balloon [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Maturity Date				Mar. 26, 2020
Cherokee Loan and Security Agreement [Member]
Line of Credit Facility [Line Items]
Placement Agent Fees				$ 60,000
Proceeds from Debt, Net of Issuance Costs				80,000
Repayments of Debt				1,015,000
Legal Fees				19,000
State Filing Fees				3,000
Debt Instrument, Periodic Payment, Interest				4,000
Notes and Loans, Noncurrent		$ 1,125,000		1,125,000		$ 1,200,000
Debt Related Commitment Fees and Debt Issuance Costs				$ 19,000
Cherokee Loan and Security Agreement [Member] | New Participations [Member]
Line of Credit Facility [Line Items]
Contingent Consideration Additional Restricted Shares Issuable				196,000
Debt Instrument, Interest Rate, Stated Percentage							8.00%
Debt Instrument, Face Amount							$ 511,000
Cherokee Loan and Security Agreement [Member] | Series A Debentures and CAM Bridge Loan [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Periodic Payment, Interest	$ 15,000
Debt Instrument, Interest Rate, Stated Percentage	15.00%
Debt Instrument, Face Amount	$ 689,000
Cherokee Loan and Security Agreement [Member] | Cherokee Financial LLC [Member]
Line of Credit Facility [Line Items]
Contingent Consideration Additional Restricted Shares Issuable				600,000
Stock Issued During Period, Shares, Restricted Stock Award, Gross				1,800,000
Cherokee Loan and Security Agreement [Member] | Cantone Research Inc [Member]
Line of Credit Facility [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross				200,000

Line of Credit and Debt - Line

Line of Credit and Debt - Line of Credit with Crestmark Bank ("Crestmark") (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015	Dec. 31, 2015
Line of Credit Facility [Line Items]
Interest Expense, Debt		$ 0		$ 5,000
Imperium Line Of Credit [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Fee Amount		69,000		69,000
Interest Expense, Debt		0		39,000
Line Of Credit Facility Termination Fee					$ 50,000
Debt Related Commitment Fees and Debt Issuance Costs				137,000
Crestmark Bank [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity	$ 1,500,000		$ 1,500,000
Minimum Loan Balance	500,000		500,000
Interest Expense, Debt	16,000	21,000	47,000	21,000
Debt Instrument, Face Amount	736,000		736,000		$ 777,000
Imperium [Member]
Line of Credit Facility [Line Items]
Debt Instrument, Fee Amount	50,000		50,000
Crestmark Loan And Security Agreeement [Member]
Line of Credit Facility [Line Items]
Minimum Net Worth Required for Compliance	650,000		650,000
Debt Related Commitment Fees and Debt Issuance Costs	8,000	$ 6,000	24,000	$ 8,000
Crestmark Loan And Security Agreeement [Member] | Crestmark Bank [Member]
Line of Credit Facility [Line Items]
Monthly Reduction of Inventory Sub-Cap Limit	10,000		10,000
Inventory Sub-Cap Limit	$ 350,000		$ 350,000
Line of Credit Facility, Borrowing Capacity, Description			The Maximum Amount is subject to an Advance Formula comprised of: 1) 90% of Eligible Accounts Receivables (excluding, receivables remaining unpaid for more than 90 days from the date of invoice and sales made to entities outside of the United States), and 2) up to 40% of eligible inventory plus up to 10% of Eligible Generic Packaging Components not to exceed the lesser of $500,000 (“Inventory Sub-Cap Limit”), or 100% of the Eligible Accounts Receivable.
Debt Instrument, Debt Default, Description of Violation or Event of Default			The Extra Rate is the Companys then current interest rate plus 12.75% per annum.
Line of Credit Facility, Interest Rate at Period End	9.35%		9.35%
Payments of Debt Issuance Costs			$ 12,000
Legal Fees			$ 3,000
Percentage of Net Income, Increase	50.00%		50.00%
Crestmark Loan And Security Agreeement [Member] | Imperium [Member]
Line of Credit Facility [Line Items]
Line of Credit Facility, Interest Rate During Period			12.00%

Line of Credit and Debt - First

Line of Credit and Debt - First Niagara : Mortgage Consolidation Loan (Details Textual) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015
Line of Credit Facility [Line Items]
Interest Expense, Debt	$ 0	$ 5,000

Line of Credit and Debt - Deben

Line of Credit and Debt - Debenture Financing/Bridge Loan (Details Textual) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015
Schedule of Capitalization, Long-term Debt [Line Items]
Interest Expense, Debt	$ 0	$ 5,000
Series A Debentures [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Interest Expense, Debt	$ 0	$ 22,000

Line of Credit and Debt - Lin28

Line of Credit and Debt - Line of Credit with Imperium Commercial Finance, LLC ("Imperium") (Details Textual)	3 Months Ended	9 Months Ended
	Sep. 30, 2015USD ($)	Sep. 30, 2015USD ($)
Line of Credit Facility [Line Items]
Interest Expense, Debt	$ 0	$ 5,000
Imperium Line Of Credit [Member]
Line of Credit Facility [Line Items]
Interest Expense, Debt	0	39,000
Debt Instrument, Fee Amount	$ 69,000	69,000
Debt Related Commitment Fees and Debt Issuance Costs		$ 137,000

Stock Options and Warrants (Det

Stock Options and Warrants (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Shares, Granted	0	0
Employee Stock Option [Member]
Shares, beginning balance			1,435,000	1,295,000
Shares, Granted			830,000	340,000
Shares, Exercised			0	0
Shares, Cancelled/expired			(83,000)	(200,000)
Shares, Ending Balance	2,182,000	1,435,000	2,182,000	1,435,000
Exercisable at end of period	1,184,000	1,027,000	1,184,000	1,027,000
Weighted Average Exercise Price, at beginning of period			$ 0.13	$ 0.27
Weighted Average Exercise Price, Granted			0.11	0.12
Weighted Average Exercise Price, Cancelled/expired			0.19	0.90
Weighted Average Exercise Price, at end of period	$ 0.13	$ 0.14	0.13	0.14
Weighted Average Exercise Price, Exercisable, at end of period	$ 0.14	$ 0.15	$ 0.14	$ 0.15
Aggregate Intrinsic Value, Outstanding at end of period	$ 30,000	$ 16,300	$ 30,000	$ 16,300

Stock Options and Warrants (D30

Stock Options and Warrants (Details 1)	9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	10 years	10 years
Dividend yield	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	62.00%	63.00%
Risk-free interest rate	1.57%	1.92%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	66.00%	64.00%
Risk-free interest rate	1.94%	2.33%

Stock Options and Warrants (D31

Stock Options and Warrants (Details 2) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, Granted	0	0
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares, beginning balance			2,385,000	3,303,000
Shares, Granted			0	0
Shares, Exercised			0	0
Shares, Cancelled/expired			(325,000)	(918,000)
Shares, Ending Balance	2,060,000	2,385,000	2,060,000	2,385,000
Exercisable at end of period	2,060,000	2,385,000	2,060,000	2,385,000
Weighted Average Exercise Price, at beginning of period			$ 0.17	$ 0.17
Weighted Average Exercise Price, Cancelled/expired			0.14	0.15
Weighted Average Exercise Price, at end of period	$ 0.18	$ 0.17	0.18	0.17
Weighted Average Exercise Price, Exercisable, at end of period	$ 0.18	$ 0.17	$ 0.18	$ 0.17
Aggregate Intrinsic Value outstanding at period	$ 0	$ 0	$ 0	$ 0

Stock Options and Warrants (D32

Stock Options and Warrants (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Sep. 30, 2015	Sep. 30, 2016	Sep. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	0	0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 0		$ 0
Allocated Share-based Compensation Expense	13,000	$ 9,000	$ 49,000	$ 27,000
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			0	0
Debt Related Commitment Fees and Debt Issuance Costs	0	$ 0	$ 0	$ 100,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			830,000	340,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	$ 57,000		$ 57,000
Employee Stock Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			9 months
Employee Stock Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			20 months

Related Party Note Payable (Det

Related Party Note Payable (Details Textual) - Jaskiewicz [Member]	9 Months Ended
	Sep. 30, 2016USD ($)shares
Related Party Transaction [Line Items]
Debt Conversion, Converted Instrument, Amount | $	$ 154,279
Debt Conversion, Converted Instrument, Shares Issued | shares	1,186,765
Issue Price Per, Description	The number of common shares to be issued to Mr. Jaskiewicz was determined by a using the average closing price of the Company’s common shares for the ten (10) consecutive trading days preceding the issuance, or $0.13 per share.